AI in Healthcare
Medical AI, diagnostics, drug discovery and biotech
-
Tavneos Approval Faces a Rare FDA Reversal Over Trial Data
The FDA wants to pull its approval of Tavneos, a drug used for a rare autoimmune form of vasculitis. The…
Read More » -
GLP-1s Meet a Rising Eating Disorder Crisis
GLP-1 weight-loss drugs have become one of the biggest biotech breakthroughs of the last decade. Now, as millions use them…
Read More » -
GLP-1s Meet a Rising Eating Disorder Crisis
GLP-1 weight-loss drugs rank among the biggest biotech breakthroughs of the last decade. Yet for people with eating disorders, the…
Read More » -
Death Clock Turns Bloodwork Into a Deadline
Death Clock put death on the calendar. The AI-powered longevity app told the author they were scheduled to die on…
Read More » -
Microsoft’s Medical AI Takes Aim at the Hardest Diagnoses
Microsoft’s newest medical AI has delivered a striking result: in a controlled simulation, it diagnosed complex cases more than twice…
Read More » -
Pathos AI Raises $237 Million for Cancer Drug Pipeline
Pathos AI just put a $3 billion price tag on artificial intelligence for cancer treatment. The New York City biotechnology…
Read More » -
OpenAI Buys Orchestra Bio to Build Drug Development Agents
OpenAI is buying Orchestra Bio. The acquisition brings the biotech startup’s team and technology into OpenAI’s Rosalind, a suite of…
Read More » -
AI Money Moves Into Brain Implants Built to Fight Cancer
A new investment is pushing artificial intelligence and brain-computer interfaces into one of medicine’s most challenging areas: cancer. OpenAI’s venture…
Read More » -
Breast Cancer AI Moves From Risk Prediction to Precision Treatment
Breast cancer care is entering a new phase, with AI helping doctors estimate recurrence risk, spot disease earlier, and shape…
Read More » -
Johns Hopkins and OpenEvidence Redesign Medicine for the AI Era
Medical education is entering an AI-defined era. OpenEvidence and Johns Hopkins Medicine announced a strategic collaboration on October 13, 2026,…
Read More »